In clinical practice, COMP is used as a prognostic marker for joint injury, a biomarker for idiopathic pulmonary fibrosis, and a biomarker for cartilage degeneration-associated osteoarthritis and rheumatoid arthritis (Posey et al., 2018). The gene discussed is COMP; the disease is pulmonary fibrosis.